Evidence map›Paper›PMID 12861075›Full record

ReviewProceedings of the National Academy of Sciences of the United States of America2003

The two faces of transforming growth factor beta in carcinogenesis.

Anita B Roberts, Lalage M Wakefield

Abstract readCommentReview
In one paragraph

Review in Proceedings of the National Academy of Sciences of the United States of America, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 357 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
357citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

357 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Current Methodologies to Assess Cellular Senescence in Cancer.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Role of Elevated Serum TGF-β1 and the Common PromoterMedicina (Kaunas, Lithuania) · 2024
    Article
  20. Article

297 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Anita B RobertsLaboratory of Cell Regulation and Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-5055, USA. robertsa@dce41.nci.nih.gov
Lalage M Wakefield

Funding

TGF-betas in breast cancer progressionZIABC005785 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WAKEFIELD, LALAGE · 2009 to 2025
$16.4M
TGF-betas in breast cancer progressionZ01BC005785 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WAKEFIELD, LALAGE · 1996 to 2008
$1.9M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsFemaleGenes, Tumor SuppressorHumansMammary Neoplasms, ExperimentalMiceModels, BiologicalNeoplasm MetastasisNeoplasmsOncogenesSignal TransductionTransforming Growth Factor betaTumor Suppressor ProteinsTransforming Growth Factor betaTumor Suppressor Proteins

Identifiers

PMID12861075
PMCPMC166359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.